Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
Objective: To understand the long-term experience of patients receiving ide-cel chimeric antigen receptor T (CAR T) cell therapy for relapsed or refractory multiple myeloma in the pivotal phase 2 KarMMa trial.Methods: This qualitative study analyzed semi-structured patient interviews 6-24 months aft...
| Autores: | , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universidad de Navarra |
| Repositorio: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Idioma: | inglés |
| OAI Identifier: | oai:dadun.unav.edu:10171/66567 |
| Acceso en línea: | https://hdl.handle.net/10171/66567 |
| Access Level: | acceso abierto |
| Palabra clave: | CAR T cell therapy Idecabtagene vicleucel Patient experience Patient-reported outcomes Relapsed or refractory multiple myeloma Triple-class exposed |
| id |
ES_eb45582a769ec81ff0afd2ddb77907ef |
|---|---|
| oai_identifier_str |
oai:dadun.unav.edu:10171/66567 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trialDelforge, M. (Michel)|||/items/f642fb6d-d632-430b-9601-260fd0bf5b45Rodriguez-Otero, P. (Paula)|||/items/bb21b679-c3ea-4d5a-9939-f330219406c8Shah, N. (Nina)|||/items/789f2c08-5c96-4021-a173-d1f1a84d1889Moshkovich, O. (Olga)|||/items/2f39c7d3-c301-484d-8ec8-dbc393e28a3fBraverman, J. (Julia)|||/items/30b8e061-2bf8-4fa3-8dbf-10d1d47b4411Dhanda, D.S. (Devender S.)|||/items/a3e76068-e8a1-45d3-a63d-e6a49c8e71f5Lanar, S. (Sally)|||/items/2479e82f-66e4-471c-8560-e69a23486cdfDevlen, J. (Jennifer)|||/items/aeeabdc0-ca00-4fbf-8b5c-3cb604fc4f88Miera, M. (Matthew)|||/items/5b6df491-f4fe-4e82-b0dc-aca9e92ac269Gerould, H. (Heather)|||/items/0e4669a7-6524-4624-8f3f-3380673fd839Campbell, T.B. (Timothy B.)|||/items/8699cd08-6cb8-45f9-abbe-f79cef487a10Munshi, N.C. (Nikhil C.)|||/items/6fcdcaca-fb7e-4b1a-9960-f5fe2410094dCAR T cell therapyIdecabtagene vicleucelPatient experiencePatient-reported outcomesRelapsed or refractory multiple myelomaTriple-class exposedObjective: To understand the long-term experience of patients receiving ide-cel chimeric antigen receptor T (CAR T) cell therapy for relapsed or refractory multiple myeloma in the pivotal phase 2 KarMMa trial.Methods: This qualitative study analyzed semi-structured patient interviews 6-24 months after ide-cel infusion. Thematic analysis with quantitative and longitudinal analyses explored patient perceptions of ide-cel treatment experience, advantages and disadvantages, and long-term health-related quality of life impact. Patient journeys were developed from narrative analysis of perceived treatment benefits with known remission length.Results: Interviews with 45 patients 6-24 months postinfusion were analyzed; all reported >= 1 ide-cel treatment advantage, most often related to efficacy (n = 42/45, 93%), few or no side effects (n = 35/45, 78%), and avoidance of other treatments (n = 34/45, 76%). Patients generally reported 6-month improvements in physical health, functioning, emotional well-being, social life, and outlook on the future; these improvements mostly remained stable through 18 and 24 months. The most common patient journeys comprised physical, func-tioning, or emotional benefit with remission < 2 years.Conclusions: Longitudinal analysis of patient experiences showed sustained benefits and preference for ide-cel up to 24 months after treatment.Trial Registration Number and Date: NCT03361748. December 5, 2017.Dadun. Depósito Académico Digital Universidad de Navarra20232023-06-0720232023-01-0120232023-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/66567reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/665672026-06-21T12:47:57Z |
| dc.title.none.fl_str_mv |
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial |
| title |
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial |
| spellingShingle |
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial Delforge, M. (Michel)|||/items/f642fb6d-d632-430b-9601-260fd0bf5b45 CAR T cell therapy Idecabtagene vicleucel Patient experience Patient-reported outcomes Relapsed or refractory multiple myeloma Triple-class exposed |
| title_short |
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial |
| title_full |
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial |
| title_fullStr |
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial |
| title_full_unstemmed |
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial |
| title_sort |
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial |
| dc.creator.none.fl_str_mv |
Delforge, M. (Michel)|||/items/f642fb6d-d632-430b-9601-260fd0bf5b45 Rodriguez-Otero, P. (Paula)|||/items/bb21b679-c3ea-4d5a-9939-f330219406c8 Shah, N. (Nina)|||/items/789f2c08-5c96-4021-a173-d1f1a84d1889 Moshkovich, O. (Olga)|||/items/2f39c7d3-c301-484d-8ec8-dbc393e28a3f Braverman, J. (Julia)|||/items/30b8e061-2bf8-4fa3-8dbf-10d1d47b4411 Dhanda, D.S. (Devender S.)|||/items/a3e76068-e8a1-45d3-a63d-e6a49c8e71f5 Lanar, S. (Sally)|||/items/2479e82f-66e4-471c-8560-e69a23486cdf Devlen, J. (Jennifer)|||/items/aeeabdc0-ca00-4fbf-8b5c-3cb604fc4f88 Miera, M. (Matthew)|||/items/5b6df491-f4fe-4e82-b0dc-aca9e92ac269 Gerould, H. (Heather)|||/items/0e4669a7-6524-4624-8f3f-3380673fd839 Campbell, T.B. (Timothy B.)|||/items/8699cd08-6cb8-45f9-abbe-f79cef487a10 Munshi, N.C. (Nikhil C.)|||/items/6fcdcaca-fb7e-4b1a-9960-f5fe2410094d |
| author |
Delforge, M. (Michel)|||/items/f642fb6d-d632-430b-9601-260fd0bf5b45 |
| author_facet |
Delforge, M. (Michel)|||/items/f642fb6d-d632-430b-9601-260fd0bf5b45 Rodriguez-Otero, P. (Paula)|||/items/bb21b679-c3ea-4d5a-9939-f330219406c8 Shah, N. (Nina)|||/items/789f2c08-5c96-4021-a173-d1f1a84d1889 Moshkovich, O. (Olga)|||/items/2f39c7d3-c301-484d-8ec8-dbc393e28a3f Braverman, J. (Julia)|||/items/30b8e061-2bf8-4fa3-8dbf-10d1d47b4411 Dhanda, D.S. (Devender S.)|||/items/a3e76068-e8a1-45d3-a63d-e6a49c8e71f5 Lanar, S. (Sally)|||/items/2479e82f-66e4-471c-8560-e69a23486cdf Devlen, J. (Jennifer)|||/items/aeeabdc0-ca00-4fbf-8b5c-3cb604fc4f88 Miera, M. (Matthew)|||/items/5b6df491-f4fe-4e82-b0dc-aca9e92ac269 Gerould, H. (Heather)|||/items/0e4669a7-6524-4624-8f3f-3380673fd839 Campbell, T.B. (Timothy B.)|||/items/8699cd08-6cb8-45f9-abbe-f79cef487a10 Munshi, N.C. (Nikhil C.)|||/items/6fcdcaca-fb7e-4b1a-9960-f5fe2410094d |
| author_role |
author |
| author2 |
Rodriguez-Otero, P. (Paula)|||/items/bb21b679-c3ea-4d5a-9939-f330219406c8 Shah, N. (Nina)|||/items/789f2c08-5c96-4021-a173-d1f1a84d1889 Moshkovich, O. (Olga)|||/items/2f39c7d3-c301-484d-8ec8-dbc393e28a3f Braverman, J. (Julia)|||/items/30b8e061-2bf8-4fa3-8dbf-10d1d47b4411 Dhanda, D.S. (Devender S.)|||/items/a3e76068-e8a1-45d3-a63d-e6a49c8e71f5 Lanar, S. (Sally)|||/items/2479e82f-66e4-471c-8560-e69a23486cdf Devlen, J. (Jennifer)|||/items/aeeabdc0-ca00-4fbf-8b5c-3cb604fc4f88 Miera, M. (Matthew)|||/items/5b6df491-f4fe-4e82-b0dc-aca9e92ac269 Gerould, H. (Heather)|||/items/0e4669a7-6524-4624-8f3f-3380673fd839 Campbell, T.B. (Timothy B.)|||/items/8699cd08-6cb8-45f9-abbe-f79cef487a10 Munshi, N.C. (Nikhil C.)|||/items/6fcdcaca-fb7e-4b1a-9960-f5fe2410094d |
| author2_role |
author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Dadun. Depósito Académico Digital Universidad de Navarra |
| dc.subject.none.fl_str_mv |
CAR T cell therapy Idecabtagene vicleucel Patient experience Patient-reported outcomes Relapsed or refractory multiple myeloma Triple-class exposed |
| topic |
CAR T cell therapy Idecabtagene vicleucel Patient experience Patient-reported outcomes Relapsed or refractory multiple myeloma Triple-class exposed |
| description |
Objective: To understand the long-term experience of patients receiving ide-cel chimeric antigen receptor T (CAR T) cell therapy for relapsed or refractory multiple myeloma in the pivotal phase 2 KarMMa trial.Methods: This qualitative study analyzed semi-structured patient interviews 6-24 months after ide-cel infusion. Thematic analysis with quantitative and longitudinal analyses explored patient perceptions of ide-cel treatment experience, advantages and disadvantages, and long-term health-related quality of life impact. Patient journeys were developed from narrative analysis of perceived treatment benefits with known remission length.Results: Interviews with 45 patients 6-24 months postinfusion were analyzed; all reported >= 1 ide-cel treatment advantage, most often related to efficacy (n = 42/45, 93%), few or no side effects (n = 35/45, 78%), and avoidance of other treatments (n = 34/45, 76%). Patients generally reported 6-month improvements in physical health, functioning, emotional well-being, social life, and outlook on the future; these improvements mostly remained stable through 18 and 24 months. The most common patient journeys comprised physical, func-tioning, or emotional benefit with remission < 2 years.Conclusions: Longitudinal analysis of patient experiences showed sustained benefits and preference for ide-cel up to 24 months after treatment.Trial Registration Number and Date: NCT03361748. December 5, 2017. |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023 2023-06-07 2023 2023-01-01 2023 2023-01-01 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/10171/66567 |
| url |
https://hdl.handle.net/10171/66567 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra |
| instname_str |
Universidad de Navarra |
| reponame_str |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| collection |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869423213400817664 |
| score |
15,301629 |